Core Viewpoint - Guosheng Technology has been ordered by the Beijing Securities Regulatory Commission to rectify its financial reporting and internal control issues, which may lead to potential compensation claims from affected investors [1][2]. Summary by Sections Company Issues - Guosheng Technology has been found to have inaccurate revenue and cost recognition in its landscaping business, failing to adjust accounting estimates in a timely manner, which has resulted in inaccurate disclosures in the 2022 annual report and the 2023 semi-annual report [2]. - The company did not follow proper procedures for external borrowing, with a subsidiary treating 87.5 million yuan in external loans as project prepayments without reporting to management [2]. - There are deficiencies in internal controls for the newly added photovoltaic business segment, including issues in project management, supplier qualification management, inventory management, and external borrowing [2]. Investor Compensation - Investors who purchased shares between April 27, 2023, and September 19, 2025, and still hold them may voluntarily register for compensation through the "Sina Investor Rights Protection Platform" [3]. - The specific compensation range will be determined by the court [3].

Core Viewpoint - The company, Zhengping Road and Bridge Construction Co., Ltd. (*ST Zhengping*), is facing significant financial and regulatory challenges, including a warning of delisting due to an audit report that could not express an opinion on its 2024 financials, alongside ongoing losses and non-operational fund occupation issues [2][3]. Financial Performance - The company reported a net profit attributable to shareholders of -484 million yuan for 2024 and -88.12 million yuan for the first half of 2025, indicating continued financial distress [2][5]. - Revenue for 2024 was 1.362 billion yuan, which represents a year-on-year decline of 28.53%. For the second quarter of 2025, revenue was 344 million yuan, down 37.77% year-on-year [5]. Regulatory Issues - The company received an administrative penalty from the Qinghai Securities Regulatory Bureau, which included a fine of 1.5 million yuan and warnings to several executives for violations of securities laws [3]. - Investors who suffered losses from April 29, 2022, to January 22, 2024, are eligible to file claims for compensation [3]. Company Background - Zhengping Road and Bridge was established on March 18, 1996, with a registered capital of approximately 699.62 million yuan. The company is primarily engaged in infrastructure construction and related industries [4][5]. - The company has 955 employees and operates 42 subsidiaries, indicating a broad operational footprint [5]. Risk Factors - The company has a high debt ratio, with asset-liability ratios of 90.92%, 90.60%, and 92.22% for the years 2024 and the first half of 2025, suggesting potential liquidity issues [5]. - There are numerous risk alerts associated with the company, including 526 internal risks and 831 external risks, indicating a challenging operational environment [5].

Core Viewpoint - The court has supported investors in their claims against Yitong Century Technology Co., Ltd. (stock code: 300310) for securities fraud, allowing eligible investors to participate in the compensation process [1][2]. Summary by Relevant Sections Company Background - Yitong Century completed the acquisition of Beitai Health in October 2016, which became a wholly-owned subsidiary and was included in Yitong's consolidated financial statements [1]. Fraudulent Activities - From May 1 to December 31, 2017, Beitai Health engaged in financial fraud, inflating revenue by 97.34 million yuan, costs by 52.61 million yuan, and total profit by 40.84 million yuan, which represented 3.7%, 9.75%, and 15.67% of Yitong's reported figures for that period, respectively [1]. Legal Proceedings - Investors who purchased Yitong Century stock between April 3, 2018, and November 4, 2022, and held the stock until the market close on November 4, 2022, are eligible to file claims [2]. Successful Cases - Lawyer Wang Jinlong has a history of successful claims for investors in various companies, including Yitong Century, indicating a strong track record in securities fraud cases [3]. Required Documentation for Claims - Investors need to prepare specific documents for the claims process, including a securities account confirmation, a copy of their ID, and relevant signed materials. The lawyer will guide investors through the process without requiring their presence in court [4].

Group 1 - The core issue is that Jihua Group is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which could lead to legal consequences for the company [2] - On August 12, Jihua Group reported a transaction volume of 3.964 billion yuan, with a net outflow of 663 million yuan from major investors [2] - Investors who suffered losses due to the company's failure to disclose information accurately and timely can seek compensation, specifically those who bought shares between the company's listing and the close on August 8, 2025 [2] Group 2 - The third special meeting of the independent directors of Jihua Group's sixth board was held on April 25, 2025, with all three independent directors present, confirming the legality and validity of the meeting [3] - The meeting unanimously approved several proposals, including those related to the actual and expected amounts of daily related transactions for 2024 and 2025 [3] - Jihua Group has invested in 42 enterprises and participated in 1,364 bidding projects [3]

Group 1 - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (*ST Suwu) faced its eighth consecutive trading halt on July 23 due to significant operational challenges stemming from a contract termination with its subsidiary REGEN Biotech, Inc. [1] - REGEN Biotech announced on July 18 that it had sent a termination notice to Datuo Medical (Shanghai) Co., Ltd., which will result in the loss of exclusive distribution rights for the AestheFill product in mainland China [1] - The termination of the distribution agreement is expected to lead to a substantial decrease in revenue and profit for *ST Suwu's medical aesthetics segment in the second half of 2025 [1] Group 2 - On July 13, *ST Suwu received a notice from the China Securities Regulatory Commission (CSRC) regarding administrative penalties for inflating revenue, costs, and profits, with false records in annual reports from 2020 to 2023 [2] - The CSRC plans to impose a fine of 10 million yuan and issue warnings to related personnel, which may trigger mandatory delisting due to serious violations of the Shanghai Stock Exchange listing rules [2] - Following the CSRC's notice, *ST Suwu has been placed under a delisting risk warning by the Shanghai Stock Exchange since July 14 [2]

Group 1 - The core point of the news is that *ST Pan Hai (stock code: 000046) is facing delisting due to its stock price being below 1 yuan for twenty consecutive trading days, with the delisting effective from February 7, 2024 [1] - On February 6, 2024, *ST Pan Hai's chairman, Luan Xianzhou, received an administrative penalty from the Beijing Securities Regulatory Bureau for insider trading and leaking insider information related to Minsheng Holdings in 2016, resulting in a confiscation of illegal gains amounting to 5.6377 million yuan and a fine three times the illegal gains [1] - Additionally, on February 5, 2024, *ST Pan Hai received a notice from the China Securities Regulatory Commission regarding an investigation into suspected violations of information disclosure laws, which is currently ongoing [1] Group 2 - Investors who purchased *ST Pan Hai shares on or before February 5, 2024, and sold or continued to hold them after February 6, 2024, may be eligible to file for compensation, although final eligibility will be determined by the court [2]

Core Points - The resignation of director Shao Yinshi from Yangzi New Materials Co., Ltd. due to personal reasons was announced on July 10, 2025 [1] - The company reported a significant decline in its Q1 2025 financial performance, with total revenue of 70.618 million yuan, a year-on-year decrease of 19.11%, and a net profit attributable to shareholders of -4.6539 million yuan, a year-on-year decline of 6.16% [1] - The company faced administrative penalties from the China Securities Regulatory Commission for significant omissions in its annual report, including undisclosed related party fund occupation and false records [2] Financial Performance - As of the end of Q1 2025, Yangzi New Materials had a total revenue of 70.618 million yuan, down 19.11% year-on-year [1] - The net profit attributable to shareholders was -4.6539 million yuan, reflecting a 6.16% decrease compared to the previous year [1] - The company reported a basic earnings per share of -0.01 yuan and a weighted average return on net assets of -1.76% [1] Regulatory Issues - On November 9, 2023, Yangzi New Materials received an administrative penalty decision from the China Securities Regulatory Commission for major omissions in its annual report [2] - The company was found to have inflated its revenue by approximately 137.1 million yuan in 2020, which accounted for about 11% of its annual revenue [2] - Investors who purchased shares between April 29, 2019, and December 29, 2022, may be eligible to file claims for damages [2]

Group 1 - The core point of the article is that Suzhou Tianwo Technology Co., Ltd. has lifted its delisting risk warning and changed its stock name back to Tianwo Technology, following a significant improvement in its financial performance [1][2] - The company announced a one-day trading suspension on April 14, 2025, with trading resuming on April 15, 2025, and the stock price limit increased from 5% to 10% [1] - After resuming trading, Tianwo Technology experienced consecutive trading limits, achieving a total of 11 trading days with price increases [1] Group 2 - Tianwo Technology's financial performance for the year 2023 includes a revenue of 3.771 billion yuan and a net profit attributable to shareholders of 1.198 billion yuan, while the net asset at the end of 2023 was 114 million yuan [2] - The company faced delisting risk due to negative net assets reported in its 2022 annual report and consecutive years of negative net profit [2] - The company has received 108 litigation claims from minority shareholders, totaling 13.8419 million yuan, along with additional claims from 68 shareholders amounting to 13.7328 million yuan [1][2]

Group 1 - The company *ST Jianyi disclosed that as of June 17, it has faced new lawsuits and arbitration cases with a total amount exceeding 83.67 million yuan, accounting for approximately 10.42% of its latest audited net assets [3] - The company is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, with a final penalty issued in April 2023 [3][4] - The company has been fined 1.5 million yuan by the Shenzhen Securities Regulatory Bureau for failing to disclose information properly, particularly regarding transactions with subsidiaries of Evergrande Group [3][4] Group 2 - As of the end of 2024, *ST Jianyi's audited net assets are negative, leading to a delisting risk warning from the Shenzhen Stock Exchange [4] - The company has faced continuous operating capability uncertainties, with negative net profits for the last three accounting years [4] - Shareholders may seek compensation due to the company's information disclosure violations, as per the Civil Code and Securities Law [4]

Group 1 - The company reported a total revenue of 351 million yuan in Q1 2025, a year-on-year decrease of 14.53% [1] - The net profit attributable to shareholders was a loss of 148 million yuan, compared to a loss of 93.17 million yuan in the same period last year [1] - The company’s cash flow from operating activities was 3.12 million yuan, an increase of 48.06% year-on-year [1] Group 2 - In the 2024 annual report, the company reported a net profit loss ranging from 1.05 billion to 1.26 billion yuan, compared to a loss of 626 million yuan in the previous year [1] - The company faced penalties from the China Securities Regulatory Commission for false statements in its 2022 annual report, which inflated total profits by 11.86 million yuan [2] - Legal consultations are available for investors who purchased shares between April 21, 2023, and December 24, 2023, and may seek compensation for losses [2]